Angel Physicians Fund

Alphyn Biologics is a life science company focused on developing innovative drug therapies for skin diseases, particularly severe and common skin infections. The company's primary target is infections caused by drug-resistant bacteria, specifically methicillin-resistant Staphylococcus aureus (MRSA). Utilizing its proprietary Multi-Target Therapeutic (MTT) platform, Alphyn Biologics creates topical treatments derived from a tropical plant known for its natural antibacterial properties. This approach aims to address shortcomings in existing treatments, such as efficacy, side effects, and patient tolerability, ultimately providing a safe and effective solution for patients suffering from bacterial skin infections.

PanTher Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative drug-delivery treatments for cancer. The company has created a proprietary platform that enables targeted and sustained drug administration directly at tumor sites, significantly enhancing therapeutic efficacy while minimizing the toxic side effects commonly associated with traditional chemotherapy. This approach allows oncologists to unlock the full potential of cancer drugs, particularly in challenging cases such as pancreatic cancer, where treatment options can be limited. Founded in 2014, PanTher Therapeutics aims to improve cancer care by addressing the needs of patients suffering from life-threatening malignancies.

Elucid, located in the Boston biotech and medtech hub, specializes in enhancing the accuracy and cost-effectiveness of cardiovascular diagnostic imaging through machine learning. Its flagship product, ElucidVivo, is the first FDA-cleared software that evaluates plaque vulnerability from a single computed tomography angiography (CTA) scan, aiding in the assessment of heart attack and stroke risk as well as treatment selection. The company also collaborates with pharmaceutical firms, healthcare providers, and research organizations to offer quantitative image analysis services. By applying artificial intelligence to vascular diagnostics, Elucid aims to improve patient outcomes while providing a non-invasive and economically efficient means of capturing critical health information, thereby supporting cardiovascular pathologists in delivering comprehensive clinical insights.

S4 Medical Corp. is a medical device company based in Cleveland, Ohio, founded in 2017. The company specializes in developing innovative solutions for catheter ablation treatment, specifically targeting atrial fibrillation. Its primary product, the eSolution device, is designed to minimize complications to the esophagus during ablation procedures. This device allows healthcare providers to protect the esophagus and aids electrophysiologists in determining the necessary adjustments for effective treatment. S4 Medical's focus on enhancing patient safety in cardiac procedures reflects its commitment to improving outcomes in the field of electrophysiology.

Moray Medical specializes in developing advanced robotic delivery systems for structural heart therapies, particularly focusing on edge-to-edge valve leaflet repair for patients with leaky heart valves. The company aims to enhance the quality of life for individuals suffering from this condition by offering innovative solutions that enable cardiologists to perform mitral valve clip therapies more safely and cost-effectively. Moray Medical's technology features a compact, reusable fluid-drive system that allows precise movement of flexible delivery catheters, facilitated by a digital interface akin to operating a computer cursor. This approach streamlines the treatment process, making life-saving heart valve therapies more accessible to a greater number of patients.

Foldax, Inc. is a company based in Salt Lake City, Utah, that specializes in the design and manufacture of synthetic heart valves for patients with aortic, mitral, or tricuspid valve disease. Founded in 2013, Foldax focuses on developing innovative heart valves made from a unique biopolymer technology that aims to provide non-thrombogenic solutions at significantly lower costs compared to traditional artificial or tissue valves. Their valves can be delivered through both transcatheter and surgical methods, offering a potential treatment option that may reduce or eliminate the need for long-term anticoagulant medications, thereby minimizing associated risks and side effects.